Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$2.77
-$0.07(-2.46%)
At close: 4:00 PM EDT
$2.77
-$0.07(-2.46%)
Day’s Range― - ―
52-Week Range$2.56 - $6.44
Previous CloseN/A
Volume1.91M
Average Volume (3M)4.02M
Market Cap
$579.53M
Enterprise Value$87.61
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume2,499,239
30 Day Avg. Volume4,018,388
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.25Price Target Upside450.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$1.88K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet & Pro Forma Cash RunwayA debt-free balance sheet and ~$535M pro forma cash materially increase Altimmune’s ability to fund global Phase III start‑up and multi-year trials without immediate dilutive financing. This financial flexibility supports longer-term execution, CRO commitments, and clinical supply obligations through registrational milestones.
Regulatory Recognition — Breakthrough TherapyBreakthrough Therapy designation and alignment with FDA/EMA on PERFORMA protocol de‑risks regulatory pathway, enables more frequent regulator engagement, and can accelerate review timelines. This structural recognition raises the program’s probability of efficient development and potential expedited access if trials confirm benefit.
Positive Phase II Signals Across IndicationsRobust Phase II efficacy and tolerability in RECLAIM (AUD) plus prior IMPACT MASH signals strengthen pemvidutide’s value proposition across metabolic and liver indications. Consistent biomarker and clinical endpoints improve confidence in translatability to registrational studies and increase partnership and label expansion optionality.
Bears Say
Persistent Cash Burn And Weak Cash GenerationOngoing negative operating and free cash flow create structural reliance on capital markets or partnerships until commercial revenue emerges. Despite pro forma proceeds, sustained development costs for multi‑year Phase III programs mean dilution or new funding rounds remain likely if timelines extend or additional programs are pursued.
Long Phase III Timelines To Registrational ReadoutA 52‑week biopsy primary endpoint and a multi‑year global Phase III create an extended horizon to potential approval and revenue, raising execution risk and capital consumption over time. Long timelines magnify the impact of operational setbacks and allow competitors more opportunity to capture market share before launch.
Intense Competitive LandscapeA crowded GLP‑1/dual‑ and triple‑agonist field heightens the need for clear clinical differentiation on tolerability and liver efficacy. Competitive entrants with established brands or broader efficacy could limit market share and pricing power, requiring stronger post‑approval evidence or strategic partnerships to secure commercial success.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $6.44 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $579.53M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.14.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (450.54% Upside)
$15.25 (450.54% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 88%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for metabolic and liver diseases. Its pipeline includes investigational candidates such as pemvidutide, a GLP-1/glucagon dual receptor agonist being studied for obesity and metabolic dysfunction–associated steatohepatitis (MASH/NASH). The company’s operations primarily involve research and development activities and advancing product candidates through clinical trials rather than commercial product sales.
ALT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$15.25
▲(450.54% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
9.34% Mutual Funds
0.68% Other Institutional Investors
73.40% Public Companies and
Individual Investors